Surgical case reports · 2026
A Case of Pathological Complete Response after "Conversion Surgery" for Initially Unresectable Locally Advanced Intrahepatic Cholangiocarcinoma.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shirakawa Yasunori, Yoh Tomoaki, Ito Takashi, Ogiso Satoshi, Ishii Takamichi, Fujimoto Masakazu, Haga Hironori, Hatano Etsuro
Аннотация
INTRODUCTION: Intrahepatic cholangiocarcinoma (iCCA) is the second most common liver cancer and has a poor prognosis. Given the recent advancements in drug therapy, the topic of so-called "conversion surgery" in biliary tract cancer, including iCCA, is evolving; however, only a few cases have been reported.
CASE PRESENTATION: A 50-year-old female was referred to our hospital for a liver tumor identified on abdominal ultrasonography. She was diagnosed with iCCA based on tumor biopsy. Due to extensive vascular and bile duct invasion, iCCA was initially considered unresectable. After 8 cycles of gemcitabine, cisplatin plus S-1 (GCS) therapy, CT revealed a partial response. Considering that microsatellite instability-high (MSI-H) was detected, we switched the regimen from GCS to pembrolizumab. However, after 1 cycle of pembrolizumab therapy, immune checkpoint inhibitor (ICI)-induced hepatitis was suspected; therefore, pembrolizumab therapy was suspended. GCS therapy was restarted, and after another 3 cycles, the iCCA was deemed resectable; therefore, conversion surgery was performed. Postoperative histopathological examination revealed a pathological complete response (pCR), and the patient remained alive more than 5 years postoperatively without recurrence or metastasis.
CONCLUSIONS: We experienced a case of pCR induced by GCS chemotherapy and pembrolizumab monotherapy. Although the direct contribution of pembrolizumab remains unclear, a possible synergistic effect with GCS chemotherapy was suggested, particularly in MSI-H tumors.
CASE PRESENTATION: A 50-year-old female was referred to our hospital for a liver tumor identified on abdominal ultrasonography. She was diagnosed with iCCA based on tumor biopsy. Due to extensive vascular and bile duct invasion, iCCA was initially considered unresectable. After 8 cycles of gemcitabine, cisplatin plus S-1 (GCS) therapy, CT revealed a partial response. Considering that microsatellite instability-high (MSI-H) was detected, we switched the regimen from GCS to pembrolizumab. However, after 1 cycle of pembrolizumab therapy, immune checkpoint inhibitor (ICI)-induced hepatitis was suspected; therefore, pembrolizumab therapy was suspended. GCS therapy was restarted, and after another 3 cycles, the iCCA was deemed resectable; therefore, conversion surgery was performed. Postoperative histopathological examination revealed a pathological complete response (pCR), and the patient remained alive more than 5 years postoperatively without recurrence or metastasis.
CONCLUSIONS: We experienced a case of pCR induced by GCS chemotherapy and pembrolizumab monotherapy. Although the direct contribution of pembrolizumab remains unclear, a possible synergistic effect with GCS chemotherapy was suggested, particularly in MSI-H tumors.